언론 · 보도자료 읽기 페이지
제목 | 언론보도 [KOICA] The Road to Vaccine Self-Sufficiency 210422 |
---|---|
|
|
첨부파일 | |
한국국제협력단(KOICA)의 '코로나19 Information Hub'에 게시한 기고문입니다.
기고자: 성백린 단장, 조희정 연구원
제목: The Road to Vaccine Self-Sufficiency
The COVID-19 pandemic has wreaked havoc across the world and exposed the vulnerabilities of individuals, societies, and countries. It revealed to us that our health systems are extremely vulnerable. But most importantly, the pandemic made us realize the importance of vaccines, more viscerally than ever.
(중략)
Vaccine technologies cannot be developed in a day. The UK has built 200 years of research achievements since Edward Jenner developed the smallpox vaccine, and now The Jenner Institute is leading the race for the COVID-19 vaccine. VITAL-Korea will endeavor to compress 200 years of research achievements in UK into the next 20 years in Korea. S. Korea, accustomed to rapid economic growth within short period, has lacked mid- to long-term R&D plans on vaccine technologies and infrastructures. The COVID-19 pandemic asks us to make a paradigm shift in the vaccine development. The conventional paradigm requires at least 10-15 years for a vaccine to be developed, if all clinical trials go smoothly. For pandemics like COVID-19 or unknown Disease-X, the vaccine development and inoculation must outpace the spread of the virus among human population. The situation asks us to develop innovative technologies to ensure developing and deploying vaccines as immediate countermeasure against the diseases. This can only be achieved through close ties in public and private sectors, and incentives in vaccine R&D and procurements.
한국국제협력단(KOICA)의 '코로나19 Information Hub'에 게시한 기고문입니다.
기고자: 성백린 단장, 조희정 연구원
제목: The Road to Vaccine Self-Sufficiency
The COVID-19 pandemic has wreaked havoc across the world and exposed the vulnerabilities of individuals, societies, and countries. It revealed to us that our health systems are extremely vulnerable. But most importantly, the pandemic made us realize the importance of vaccines, more viscerally than ever.
(중략)
Vaccine technologies cannot be developed in a day. The UK has built 200 years of research achievements since Edward Jenner developed the smallpox vaccine, and now The Jenner Institute is leading the race for the COVID-19 vaccine. VITAL-Korea will endeavor to compress 200 years of research achievements in UK into the next 20 years in Korea. S. Korea, accustomed to rapid economic growth within short period, has lacked mid- to long-term R&D plans on vaccine technologies and infrastructures. The COVID-19 pandemic asks us to make a paradigm shift in the vaccine development. The conventional paradigm requires at least 10-15 years for a vaccine to be developed, if all clinical trials go smoothly. For pandemics like COVID-19 or unknown Disease-X, the vaccine development and inoculation must outpace the spread of the virus among human population. The situation asks us to develop innovative technologies to ensure developing and deploying vaccines as immediate countermeasure against the diseases. This can only be achieved through close ties in public and private sectors, and incentives in vaccine R&D and procurements.
|
|
이전글 ▲ | [머니투데이방송] 제6회 MTN 제약바이오포럼 210423 |
다음글 ▼ | [이데일리] 성백린 "신속생산 백신 플랫폼에 지금이라도 투자해야" 210507 |